David A. Siegel Homology Medicines, Inc. Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.6 - $4.17 $51,480 - $82,566	-19,800 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$3.64 - $7.78 $25,480 - $54,460	-7,000 Reduced 26.12%	19,800 $72,000
Q3 2021 Nov 15, 2021	BUY	$6.01 - $8.71 $161,068 - $233,428	26,800 New	26,800 $211,000
Q4 2020 Feb 16, 2021	SELL	$8.92 - $13.29 $169,480 - $252,509	-19,000 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$9.94 - $16.59 $80,514 - $134,379	-8,100 Reduced 29.89%	19,000 $203,000

Q2 2020 Aug 14, 2020	SELL	$12.07 - $19.34 $3,621 - $5,802	-300 Reduced 1.09%	27,100 $412,000
Q1 2020 May 15, 2020	BUY	$12.5 - $22.04 $342,500 - $603,896	27,400 New	27,400 $426,000

66.2K

Ticker FIXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 57,402,000
Description
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nucleas...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.